Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Zelluna ASA: First Quarter 2026 results - Attachment: Zelluna-ASA-Q126-Presentation.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation titled "First Quarter 2026 Business Update and Financial Results" from Zelluna ASA dated 7 May 2026. It includes sections on key events in Q1 2026, clinical trial updates, financial updates, and outlook. The content includes operational progress, clinical trial site activations, pipeline descriptions, and financial updates. The document is about quarterly business and financial results with substantive financial data and analysis, not just a brief announcement or a presentation for investors. It is comprehensive and covers a period shorter than a full fiscal year (Q1 2026). Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-07 Norwegian
Zelluna ASA: First Quarter 2026 results - Attachment: Zelluna-ASA-Q126-Report.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'First Quarter Report' for the year 2026 and contains detailed financial data for Q1 2026, including revenues, operating expenses, profit/loss, cash flow, and cash position. It also includes a CEO statement, operational review, clinical progress, pipeline information, and other substantive business updates. The content is comprehensive and covers a period shorter than a full fiscal year, specifically the first quarter. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year. The document is not merely an announcement or a presentation but a full quarterly report with financials and management commentary. Therefore, the correct classification is IR with high confidence. Q1 2026
2026-05-07 Norwegian
Zelluna ASA: First Quarter 2026 results
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Zelluna ASA: First Quarter 2026 results' and provides detailed operational and financial highlights for the first quarter of 2026, including expenses, losses, cash position, and outlook. It mentions a webcast for investors and includes forward-looking statements and management commentary. The content is typical of a quarterly financial report containing substantive financial data and analysis for a period shorter than a full fiscal year. The document length is 4408 characters, which is sufficient to contain actual financial data rather than just an announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-07 Norwegian
Zelluna ASA: Første kvartal 2026
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial and operational update for the first quarter of 2026 from Zelluna ASA. It includes detailed financial figures such as total operating costs, pre-tax results, cash equivalents, and financial runway. It also discusses operational highlights, clinical trial progress, and future outlook. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 4557 characters, which is sufficient to contain actual financial data, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2026
2026-05-07 Norwegian
Zelluna ASA aktiverer det første kliniske senteret for ZIMA-101studien, og markerer dermed oppstart av klinisk gjennomføring
Regulatory Filings Classification · 95% confidence The document is a press release announcing the activation of the first clinical center for a phase 1 clinical study (ZIMA-101) by Zelluna ASA. It describes the start of clinical execution and mentions regulatory approvals but does not contain financial data, earnings, or detailed report content. The document is short (2787 characters) and serves as an update on clinical trial progress rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of a clinical milestone, which is best categorized under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-05-06 Norwegian
Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution
Regulatory Filings Classification · 95% confidence The document is a press release announcing the activation of the first clinical site for a Phase 1 clinical trial (ZIMA-101) by Zelluna ASA. It discusses the transition from clinical preparation to active trial execution, mentions regulatory approvals, and provides contact information. There is no financial data, no detailed report, no voting results, no management changes, no earnings information, or other regulatory filings. The content is an update on clinical trial progress, which does not fit into any of the specific financial or regulatory filing categories. Therefore, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2026-05-06 Norwegian

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.